Search Results
FDA Approvals in HCC and Cervical Cancer, Breakthrough Designation in Lung Cancer, and More
FDA Approves TAS-102, Nivolumab Breakthrough in RCC, Two Priority Reviews, and More
FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More
FDA Approvals in CINV and HER2+ Breast Cancer, Priority Review in Myelofibrosis, and More
Molecular Targeted Therapies for Advanced HCC
Dr. Rischin Discusses the Future of Cemiplimab in Cervical Cancer
Dr. Backes on the FILM Trial in Endometrial Cancer
Transforming Healthcare Feb 2020 - Breakthroughs in Cancer
Dr. Monk on the Importance of Pap Testing in Cervical Cancer
Dr. Ferguson Discusses AEs Associated With Surgery in Cervical Cancer
Dr. Ginsburg Addresses Global Disparities in Cervical Cancer
Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients
